Singapore markets closed

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3000-0.1000 (-2.94%)
At close: 1:00PM EST
3.3200 +0.02 (+0.61%)
After hours: 04:10PM EST

Orphazyme A/S

Ole MaalOees Vej 3
Copenhagen 2200
Denmark
45 39 17 82 72
http://www.orphazyme.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees180

Key executives

NameTitlePayExercisedYear born
Mr. Anders Fink Vadsholt M.B.A., M.Sc., MBAChief Financial Officer873.93kN/A1969
Mr. Christophe Bourdon M.B.A.Chief Exec. OfficerN/AN/A1970
Dr. Thomas Kirkegaard Jensen Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1977
Jennifer Jean McCannPres of Orphazyme US, Inc.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Corporate governance

Orphazyme A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.